Bullish & Foolish
Full RNAZ fundamentals All 466 on the Survival Watch

RNAZTRANSCODE THERAPEUTICS, INC.

Is Transcode Therapeutics struggling financially?

Yes, by its own account. Transcode Therapeutics told the SEC on 15 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

11/100

Critical

Cries for help

Nothing in the filings we have read reads as a plea for help.

Signs of a way out

  • Grant funding

    Grant income From time to time, we apply for grant funding from government programs and may, in the future, apply for grants from non-government sources as well.

    Form 10-Q, filed 15 May 2026. Read it on SEC.gov

  • Trial result

    Overall, we believe that Seviprotimut-L occupies a niche as a well-tolerated vaccine targeting recurrence prevention with likely differentiation on safety and tolerability.

    Form DEF 14A, filed 2 Jun 2026. Read it on SEC.gov

Sector
Biotech/Pharma
Market cap
$48.6M
Source filing
10-Q 15 May 2026
Balance sheet
30 Jun 2026

Cash runway

  • 4months

    If the burn speeds up

    Empty by Oct 2026

  • 6months

    If it eases off

    Empty by Dec 2026

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$8.4M

÷

Cash burned over the last 12 months

$19.5M

What Transcode Therapeutics told the SEC

…in the ordinary course of business. Due to the Company’s recurring and expected continuing losses from operations, the Company has concluded there is substantial doubt concerning its ability to continue as a going concern within one year of the issuance of these consolidated financial statements without additional capital becoming available. These consolidated financial statements do not include any…

TRANSCODE THERAPEUTICS, INC., Form 10-Q, filed 15 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 85.9% share-count increase The company issued stock. Each share now owns 46.2% less of the business than a year ago, before any change in the price.

Other Biotech/Pharma companies that filed the doubt